CAPR - Capricor announces positive findings from collaboration with Cedars-Sinai Medical Center researchers

Capricor Therapeutics ([[CAPR]] +10.8%) announces findings from collaboration with researchers at Cedars-Sinai Medical Center, which demonstrates the utility of pathway-enhancing culture conditions and small molecule inhibitors to retain markers of cell therapy potency.Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19."This data was the foundation of our new platform, which has allowed us to expand our reach to engineering exosomes that contain RNAs for targeted therapeutic delivery," CEO of Capricor Linda Marbán said.Capricor plans further pipeline expansion of its exosome-based product candidates by mid-2021.

For further details see:

Capricor announces positive findings from collaboration with Cedars-Sinai Medical Center researchers